Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Fate Therapeutics (FATE) Operating Margin (2016 - 2025)

Fate Therapeutics' Operating Margin history spans 14 years, with the latest figure at 2536.23% for Q4 2025.

  • For Q4 2025, Operating Margin rose 78355.0% year-over-year to 2536.23%; the TTM value through Dec 2025 reached 2222.45%, down 67982.0%, while the annual FY2025 figure was 2222.45%, 67982.0% down from the prior year.
  • Operating Margin reached 2536.23% in Q4 2025 per FATE's latest filing, down from 1995.12% in the prior quarter.
  • In the past five years, Operating Margin ranged from a high of 48.48% in Q1 2023 to a low of 6705.79% in Q2 2023.
  • Average Operating Margin over 5 years is 1636.75%, with a median of 1184.8% recorded in 2024.
  • Peak YoY movement for Operating Margin: crashed -625774bps in 2023, then skyrocketed 604006bps in 2024.
  • A 5-year view of Operating Margin shows it stood at 406.48% in 2021, then soared by 64bps to 145.23% in 2022, then tumbled by -1875bps to 2868.44% in 2023, then decreased by -16bps to 3319.78% in 2024, then rose by 24bps to 2536.23% in 2025.
  • Per Business Quant, the three most recent readings for FATE's Operating Margin are 2536.23% (Q4 2025), 1995.12% (Q3 2025), and 1938.54% (Q2 2025).